CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 261 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.35 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $806,566 | +67.1% | 68,998 | +92.1% | 0.00% | 0.0% |
| Q2 2023 | $482,550 | -37.8% | 35,912 | -23.2% | 0.00% | 0.0% |
| Q1 2023 | $775,501 | +34.4% | 46,779 | +50.7% | 0.00% | 0.0% |
| Q4 2022 | $577,115 | +91.1% | 31,042 | +31.6% | 0.00% | 0.0% |
| Q3 2022 | $302,000 | +2416.7% | 23,586 | +1284.2% | 0.00% | – |
| Q2 2022 | $12,000 | +20.0% | 1,704 | +42.4% | 0.00% | – |
| Q1 2022 | $10,000 | +25.0% | 1,197 | +2.5% | 0.00% | – |
| Q4 2021 | $8,000 | +14.3% | 1,168 | -7.4% | 0.00% | – |
| Q3 2021 | $7,000 | +16.7% | 1,262 | +13.7% | 0.00% | – |
| Q2 2021 | $6,000 | +50.0% | 1,110 | +20.8% | 0.00% | – |
| Q1 2021 | $4,000 | +300.0% | 919 | +359.5% | 0.00% | – |
| Q4 2020 | $1,000 | -85.7% | 200 | -90.5% | 0.00% | – |
| Q3 2020 | $7,000 | +133.3% | 2,100 | +200.0% | 0.00% | – |
| Q2 2020 | $3,000 | -25.0% | 700 | -30.0% | 0.00% | – |
| Q1 2020 | $4,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 589,883 | $590,000 | 1.38% |
| Broadfin Capital, LLC | 8,200,000 | $8,610,000 | 0.96% |
| Avoro Capital Advisors LLC | 1,141,149 | $1,198,000 | 0.24% |
| CORRADO ADVISORS, LLC | 190,600 | $200,000 | 0.12% |
| Baker Brothers Advisors | 5,102,153 | $5,357,000 | 0.05% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 756,311 | $794,000 | 0.04% |
| Point72 Asset Management, L.P. | 2,272,816 | $2,386,000 | 0.02% |
| AGRAN LIBBIE | 44,000 | $46,000 | 0.01% |
| COMPTON CAPITAL MANAGEMENT INC /RI | 10,000 | $11,000 | 0.01% |
| KENNEDY CAPITAL MANAGEMENT LLC | 233,171 | $245,000 | 0.00% |